We are international
• meetings TEXT SIZE   

Advancing Access to Multiple Myeloma Treatment - May 4, 2006
Sun, Jan 01, 2006

Boston Convention and Exposition Center
Boston, MA

Be an effective caregiver and advocate for your patients!
Help them gain access and information
about treatment options.
Administration, Side Effects, and Implications for Survival.

Newly released information on treatment for myeloma is critical to improving patient care. Designed to meet the needs of oncology nurses who manage the treatment of myeloma patients, this FREE CE symposium addresses the development of and access to emerging treatments.


  • Kathleen A. Colson, RN
    Dana Farber Cancer Institute
    Boston, Massachusetts

  • Deborah S. Doss, RN
    Dana Farber Cancer Institute
    Boston, Massachusetts

  • Patricia Mangan, MSN, CRNP
    University of Pennsylvania
    Philadelphia, Pennsylvania


  • Describe novel therapies of the treatment of MM and identify patients who will benefit most from these novel therapies

  • Manage new and relapsing patients who are prescribed novel therapies for the treatment of MM

  • Locate clinical trials and expanded access programs where patients can receive novel therapies for treatment of MM

  • Understand the potential use of novel therapies for special populations


6:00 - 6:30 am Registration
Program and Breakfast
6:30 - 6:40 am Welcome and Introductions
6:40 - 7:00 am The rational for patient selection and therapy
7:00 - 7:30 am Patient management: treatment administration, side effects and monitoring newly diagnosed and relapsing
7:30 - 7:45 am Practical considerations for the management of patients with myeloma (this segment will provide information on access programs)
7:45 - 8:15 am Panel Q & A Session
8:15 - 8:30 am Closing remarks

This activity is sponsored by the International Myeloma Foundation and the Institute for Continuing Healthcare Education and supported by educational grants from Celgene Corporation and Millennium Pharmaceuticals.

The International Myeloma Foundation has been assigned meeting space to support an educational offering during ONS' 31st Annual Congress. The Oncology Nursing Society's assignment of meeting space does not imply product endorsement nor does the Oncology Nursing Society assume responsibility for the educational content.